

Name of the Issue: Akums Drugs and Pharmaceuticals Limited			
1	Type of Issue	Initial Public Offer	
2	Issue Size (Rs. Mn)	18567.37*	
*Source: Prospectus dated August 1, 2024			
3	Grade of issue along with name of the rating agency		
	Name	NA	
	Grade	NA	
4	Subscription Level (Number of times)	64.64*	
* excluding Anchor Investor Portion and after removing multiple and duplicate bids			
Source: Minutes for basis of allotment dated August 2, 2024			
5	QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges		
	Particulars	%	
	(i) On Allotment **	12.92	
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2024)	14.86	
	(iii) at the end of 1st FY (March 31, 2025)*	Not Available	
	(iv) at the end of 2nd FY (March 31, 2026) *	Not Available	
	(v) at the end of 3rd FY (March 31, 2027) *	Not Available	
**Basis of Allotment (excluding pre-issue QIB holding)			
* QIB Holding not disclosed as reporting for relevant period has not been completed.			
6	Financials of the issuer		
	Parameters	1st FY (March 31,2025)*	2nd FY (March 31,2026)*
	Income from operations	Not Available	Not Available
	Net Profit/(Loss) for the period	Not Available	Not Available
	Paid-up equity share capital	Not Available	Not Available
	Reserves excluding revaluation reserves	Not Available	Not Available
* Financials not available as reporting for the relevant years has not been completed.			
7	Trading Status		
The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")			
The equity shares have not been suspended or delisted.			
	Particulars	Status	
	(i) at the end of 1st FY (March 31, 2025)*	Not Available	
	(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	
* Trading status not disclosed as the relevant fiscal years have not been completed.			
8	Change in Directors of Issuer from the disclosures in the offer document		
	Particulars	Name of Director	Appointed / Resigned
	(i) at the end of 1st FY (March 31, 2025)*	Not Available	Not Applicable
	(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available
* Changes in Directors of Issuer not updated as the relevant financial years have not been completed			

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

Particulars	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2025	Estimated Utilisation of Net Proceeds in Fiscal 2026 and beyond
Funding incremental working capital requirements of the Company	1599.10	1599.10	0.00
Funding capital expenditure of the Company	2270.90	-	2270.90
Repayment/ prepayment, in part or full, of certain of the borrowings	550.00	-	550.00
Achieving inorganic growth through acquisitions	278.70	-	278.70
General corporate purposes	1675.00	-	1675.00
Total Proceeds	6373.70	1599.10	4774.60

(ii) Actual implementation

Particulars	Amount proposed to be financed from Net Proceeds	Actual Utilisation of Net Proceeds	Unutilised Net Proceeds
Funding incremental working capital requirements of the Company	1599.10	0.00	1599.10
Funding capital expenditure of the Company	2270.90	2270.90	0.00
Repayment/ prepayment, in part or full, of certain of the borrowings	550.00	0.00	550.00
Achieving inorganic growth through acquisitions	278.70	0.00	278.70
General corporate purposes	1675.00	1675.00	0.00
Total Proceeds	6373.70	3945.90	2427.80

Source: Monitoring Agency Report dated February 10, 2025

(iii) Reasons for delay in implementation, if any Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Nil
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Nil
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Nil

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	679.00
Listing Date	6-Aug-24

Price parameters	At close of listing day August 06, 2024	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2025) ⁽¹⁾		
				Closing price	High	Low
Market Price	679.00	855.25	845.3	Not Available	Not Available	Not Available
Nifty 50*	23,992.55	25,418.55	23,995.35	Not Available	Not Available	Not Available

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2026) ⁽¹⁾			As at the end of the 3rd FY after the listing of the issue (31st March, 2027) ⁽¹⁾		
	Closing price	High	Low	Closing price	High	Low
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)**	At the end of 1st FY (March 31,2026)**	At the end of 1st FY (March 31,2027)**	
EPS (Diluted)	Company					
	Consolidated	2	-0.28	Not Available	Not Available	Not Available
	Peer Group:					
	Divi's Laboratories	2	60.27			
	Suven Pharma	1	11.8	Not Available	Not Available	Not Available
	Gland Pharma	1	46.89	Not Available	Not Available	Not Available
	Torrent Pharma	5	48.94	Not Available	Not Available	Not Available
	Alkem Laboratories	2	150.19	Not Available	Not Available	Not Available
	Eris Lifesciences	1	28.79	Not Available	Not Available	Not Available
	JB Chemicals	1	34.85	Not Available	Not Available	Not Available
	Mankind Pharma	1	47.68	Not Available	Not Available	Not Available
	Innova Captab	10	18.66	Not Available	Not Available	Not Available
	Industry Avg		49.79	Not Available	Not Available	Not Available
P/E	Company					
	Consolidated	2	NA	Not Available	Not Available	Not Available
	Peer Group:					
	Divi's Laboratories	2	74.99	Not Available	Not Available	Not Available
	Suven Pharma	1	69.54	Not Available	Not Available	Not Available
	Gland Pharma	1	42.45	Not Available	Not Available	Not Available
	Torrent Pharma	5	60.2	Not Available	Not Available	Not Available
	Alkem Laboratories	2	34.18	Not Available	Not Available	Not Available
	Eris Lifesciences	1	34.95	Not Available	Not Available	Not Available
	JB Chemicals	1	51.38	Not Available	Not Available	Not Available
	Mankind Pharma	1	44.65	Not Available	Not Available	Not Available
	Innova Captab	10	29.91	Not Available	Not Available	Not Available
	Industry Avg		49.14	Not Available	Not Available	Not Available
RoNW	Company					
	Consolidated	2	-0.57%	Not Available	Not Available	Not Available
	Peer Group:					
	Divi's Laboratories	2	11.79%	Not Available	Not Available	Not Available
	Suven Pharma	1	14.64%	Not Available	Not Available	Not Available
	Gland Pharma	1	8.85%	Not Available	Not Available	Not Available
	Torrent Pharma	5	24.15%	Not Available	Not Available	Not Available
	Alkem Laboratories	2	17.41%	Not Available	Not Available	Not Available
	Eris Lifesciences	1	15.16%	Not Available	Not Available	Not Available
	JB Chemicals	1	18.90%	Not Available	Not Available	Not Available
	Mankind Pharma	1	20.43%	Not Available	Not Available	Not Available
	Innova Captab	10	11.35%	Not Available	Not Available	Not Available
	Industry Avg		15.85%	Not Available	Not Available	Not Available
NAV per share	Company					
	Consolidated	2	49.59	Not Available	Not Available	Not Available
	Peer Group:					
	Divi's Laboratories	2	511.21	Not Available	Not Available	Not Available
	Suven Pharma	1	80.56	Not Available	Not Available	Not Available
	Gland Pharma	1	529.65	Not Available	Not Available	Not Available
	Torrent Pharma	5	202.57	Not Available	Not Available	Not Available
	Alkem Laboratories	2	862.46	Not Available	Not Available	Not Available
	Eris Lifesciences	1	190.12	Not Available	Not Available	Not Available
	JB Chemicals	1	188.37	Not Available	Not Available	Not Available
	Mankind Pharma	1	233.73	Not Available	Not Available	Not Available
	Innova Captab	10	145.2	Not Available	Not Available	Not Available
	Industry Avg		327.10	Not Available	Not Available	Not Available

Notes

* Sourced from Prospectus dated August 01, 2024.

**Not available as the relevant fiscal years have not been completed / information not disclosed

14 Any other material information

Particulars	Date	Remarks
		Not Applicable

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com